According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent recurrent/metastatic head and neck The overall response rate for patients with squamous cell carcinoma (HNSCC) is 39%. In a non-randomized, 3-arm, phase II trial (NCT02101034), the results of a group of studies have a median progression-free survival (PFS) of 5.4 months, a median overall survival (OS) of 9.5 months, and a 1-year OS The rate is 35%.
In this study, 30 patients with HNSCC unrelated to HPV progressed after platinum-based therapy for relapsed/metastatic disease and participated in the trial. Patients who had previously received cetuximab for relapse and HPV-related oropharyngeal cancer were not eligible. Patients received palbociclib from day 1 to day 21, 125 mg daily; cetuximab, with a starting dose of 400 mg/m 2 and then 250 mg/m 2 per week for a period of 28 days until the disease progressed or withdrew the study. The researchers performed imaging examinations before treatment and after every 2 cycles.
Iminyaka emaphakathi yeziguli yayiyiminyaka engama-67, kanti izindawo zesimila kwakungu-cavity yomlomo (47%), i-larynx (27%), ne-oropharynx (13%). Iziguli ezingama-20% zinama-metastases endawo, ama-27% anama-metastases akude, kanti ama-53% anakho kokubili. Iziguli eziyishumi nanhlanu (50%) zithole ukwelashwa okungu- ≥ 2.
Ezigulini ezingama-28 ezingahlolwa, i-11 (39%) yayinezimpendulo zesimila, kufaka phakathi izimpendulo ezi-3 (11%) eziphelele nezingu-8 (29%) izimpendulo eziyingxenye. Iziguli eziyishumi nane (50%) zazinezifo ezizinzile, ezi-3 (11%) iziguli zazinenqubekela phambili, kwathi ama-70% anciphisa izilonda zesimila.
Researcher Dr. Adkins said that Palbociclib and cetuximab have strong antitumor activity in platinum-resistant HPV-independent head and neck cancer, and biologically targeted therapy for HPV-independent head and neck cancer is an effective treatment strategy. . We look forward to the better results of the follow-up research.
